Omega-3 Group Research Articles

Randomized Study of the Effect of Vitamin D and Omega-3 Fatty Acids Cosupplementation as Adjuvant Chemotherapy on Inflammation and Nutritional Status in Colorectal Cancer Patients

This study aimed to evaluate the effects of vitamin D3 and omega-3 fatty acids cosupplementation on inflammation and nutritional status in colorectal cancer patients. In this clinical trial, 81 colorectal cancer patients were randomly assigned into four groups: (1) control group: receiving a vitamin D3 placebo weekly + omega-3 fatty acid placebo capsules daily; (2) omega-3 fatty acid group: receiving 2 omega-3 fatty acid capsules (each capsule containing 330 mg of omega-3 fatty acids) daily + a vitamin D3 placebo weekly; (3) vitamin D group: receiving a 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acid placebo capsules daily; (4) cosupplementation group: receiving a 50,000 IU vitamin D3 soft gel weekly + 2 omega-3 fatty acids capsules daily for 8 weeks. Before and after the intervention, height, weight, fat-free mass (FFM), serum levels of 25(OH)D, tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6), C-reactive protein (CRP), and albumin, were measured. After 8 weeks of intervention, patients who received combined vitamin D3 and omega-3 fatty acids supplements compared with omega-3, vitamin D3, and placebo groups had significantly decreased CRP and TNF-α. In addition, serum level of IL-6 was decreased significantly in omega-3, vitamin D3, and cosupplementation groups compared with baseline. Regarding nutritional status, weight, BMI, and FFM% were increased significantly in vitamin D3, omega-3, and cosupplementation groups at the end of the intervention. Vitamin D3 plus omega-3 fatty acids cosupplementation in colorectal cancer patients has beneficial impacts on inflammation and nutritional status.

Low-Dose Omega-3 Fatty Acid and Vitamin D for Anthropometric, Biochemical Blood Indices and Respiratory Function. Does it work?

Omega-3 fatty acids and vitamin D3 have beneficial effects on different blood, cardiovascular parameters and physical performance. However, the effect of low-dose omega-3 fatty acid supplementation remains unclear. 84 office workers aged 40-60years, participated in a 16-week open, randomized, placebo-controlled, parallel-group study. The experimental group received 330mg of omega-3 fatty acid and 0.005mg (200IU) of vitamin D3 per day and the control group received placebo. Anthropometric, biochemical blood and respiratory indices were measured at 12 and 16 weeks. Body mass (BM) and body mass index (BMI) significantly reduced in both the experimental (BM from 74.4±13.04 to 73.2±13.02kg, p<0.001; BMI from 25.8±4.1 to 25.4±4.3kg/m2, p<0.001) and the placebo groups (BM from 69.5±11. to 68.7±11.4kg, p<0.05; BMI from 24.1±4.0 to 23.8±4.2kg/m2, p<0.05). Omega-3 fatty acid supplementation significantly improved glucose (from 5.12±0.55 to 4.97±0.62mmol/l; p=0.05), total cholesterol (from 5.86±1.0 to 5.32±1.55mmol/l; p=0.003), and vitamin D levels (from 35.07±21.65 to 68.63±25.94nmol/l; p=0.000). Maximal oxygen consumption (from 33.7±2.4 to 36.6±3.2ml/kg/min, p=0.035), forced vital capacity (from 3.5±0.6 to 3.9±0.9l, p=0.044), forced expiratory volume (from 3.2±0.6 to 3.5±0.7l, p=0.014), and peak expiratory flow (from 6.7±1.4 to 7.5±1.6l/s, p=0.019) also slightly improved in the omega-3 fatty acid group. Daily supplementation of 330mg of omega-3 fatty acids had a slight positive impact on total cholesterol and glucose level, while there was no effect on low and high density lipoproteins, and triglycerides levels. Therefore, dose of 330mg per day seems as insufficient.

Omega-3 Suppresses Gastrointestinal Bleeding by Reducing Angiopoietin-2 Expression in LVAD Patients

Purpose Omega-3, an unsaturated fatty acid, reduces the risk of gastrointestinal bleeding (GIB) in patients with left ventricular assist devices (LVADs). However, its biological mechanism remains uncertain. This study aims to evaluate the impact of omega-3 on angiogenesis. Methods We measured inflammatory and angiogenesis biomarkers in plasma from LVAD patients by using Bio-plex ProTM Biomarker Assay kit and compared their levels between those with and without omega-3 therapy. GIB rates were also compared between the two groups by using binomial negative regression analysis. Results Among 38 patients (mean age 56.4 years, 66% male), 16 (42%) received 4 g/day omega-3 therapy. There was no significant difference in baseline characteristics between the two groups (p >0.05 for all). The GIB rate was significantly lower in the omega-3 group (0.100 event/year vs. 0.381 event/year, p Conclusion LVAD patients treated with omega-3 have significantly lower GIB rates and significantly lower angiopoietin-2 levels. The reduction in GIB rate with omega-3 may be due to the suppression of abnormal angiogenesis.

Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women

BackgroundOmega-3 polyunsaturated fatty acids (PUFAs) reduce depressive symptoms through an anti-inflammatory effect, and injection of both omega-3 PUFAs and estradiol (E2) induces antidepressant-like effects in rats by regulating the expression of inflammatory cytokines. The aims of this study were to examine the association of increased E2 during pregnancy with depressive symptoms and with inflammatory cytokines in women who were and were not supplemented with omega-3 PUFAs. MethodsPregnant women with Edinburgh Postnatal Depression Scale scores ≥9 were recruited at 12–24 weeks of gestation. The participants were randomly assigned to receive 1800 mg omega-3 fatty acids (containing 1206 mg eicosapentaenoic acid [EPA]) or placebo for 12 weeks. E2, omega-3 PUFAs, high-sensitivity C-reactive protein, interleukin-6, and adiponectin were measured at baseline and at the 12-week follow-up. Multivariable regression analyses were conducted to examine the association of the changes of E2 and omega-3 PUFAs with the changes in depressive symptoms and with the changes of inflammatory cytokines at follow-up by intervention group. ResultsOf the 108 participants in the trial, 100 (92.6%) completed the follow-up assessment including blood sampling. Multivariable regression analyses revealed that the increase of EPA and E2 was significantly associated with a decrease in depressive symptoms among the participants assigned to the omega-3 group, but not among those assigned to the placebo group. Neither E2 nor any PUFAs were associated with a change in inflammatory cytokines. ConclusionSupplementation with EPA and increased levels of E2 during pregnancy might function together to alleviate antenatal depression through a mechanism other than anti-inflammation.

Abstract # 3130 Omega-3 fatty acids improve attention in youth with attention deficit hyperactivity disorder

The aim of the study is to investigate the effect of omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplementation (mainly eicosapentaenoic acid, EPA) on clinical symptoms in youth with attention deficit hyperactivity disorder (ADHD). One hundred and five youth with a DSM-IV diagnosed ADHD were recruited from a medical centre. The youth were randomised into two groups, one group received n-3 PUFAs (1 g EPA) and the other group received placebo (1 g olive oil) for 12 weeks. The youth were assessed for their ADHD symptoms with SNAP-IV scales at baseline, weeks 2, 4, 8 and 12; ninety-eight had completed the study. Overall, there was no difference in symptom reduction between n-3 PUFAs and placebo groups. However, when we analysed the data of 29 youth with ADHD, predominantly inattentive and combined subtypes, without comorbidity such as oppositional defiant disorder, the omega-3 group (n = 17, age 9.7+ 4.2 years) had a greater reduction in inattention subscale scores and total ADHD scores at week 8 (p = .003, p = .006) and week 12 (p = .029, p = .040) than placebo group (n = 12, age 8.8+ 3.1). In conclusion, n-3 PUFAs supplementation such as EPA, improve attention in a subpopulation of youth with ADHD.

The synergistic therapeutic efficacy of vancomycin and omega-3 fatty acids alleviates Staphylococcus aureus-induced osteomyelitis in rats

Our study evaluated the synergistic impact of vancomycin and omega-3 fatty acids against osteomyelitis in a Staphylococcus aureus-induced rat model of osteomyelitis. The animals were grouped as follows: sham (group I), osteomyelitis (group II, control), vancomycin (20 mg/kg body weight, group III), omega-3 fatty acids (20 mg/kg body weight, group IV) and vancomycin (20 mg/kg body weight) + omega-3 fatty acids (20 mg/kg body weight) (group V). Lipid peroxidation, superoxide dismutase (SOD), glutathione peroxidase (Gpx), catalase, reduced glutathione (GSH), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were measured. The determination of bacterial growth and histopathological analyses were carried out. The lipid peroxidation, GSH, SOD, catalase and Gpx levels recovered to near-normal levels following combined treatment with vancomycin and omega-3 fatty acids. The TNF-α and IL-6 levels were reduced to near-normal levels. Combined supplementation with vancomycin and omega-3 fatty acids significantly reduced bacterial growth in bone and the implanted wire. Furthermore, the bone infection levels and histopathological score were reduced. In summary, combined treatment with vancomycin and omega-3 fatty acids was effective against bacterial growth and bone infection compared to monotherapy with vancomycin or omega-3 fatty acids.

The effects of omega-3 fatty acids on the newborn rat hyperoxic lung injury

Objective: Bronchopulmonary dysplasia (BPD) is an important cause of morbidity in preterms. Inflammation plays a central role in the pathogenesis of the disease while omega-3 fatty acids are known to have anti-inflammatory effects. In this study, we examined the effects of supplementary omega-3 fatty acids on hyperoxic lung injury.Methods: Experimental hyperoxic lung injury induced newborn 3-day-old rats were monitored in a confined hyperoxic environment with an oxygen concentration of 90–95% for a 2-week period. Rats were divided into three groups as placebo, low-dose Omega-3, and high-dose Omega-3. During the 2-week study period, low and high-dose Omega-3 groups were given 300 and 600 mg/kg/day omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) respectively, while those in placebo received the same amount of serum physiologic. At the end of the 2-week study, lungs of all the rats were removed and morphologic evaluation under light microscopy was performed. Mean cord length (Lm), alveolar surface area (SA), and alveolar wall thickness (Wt) were calculated to find out whether a statistically significant difference between groups existed.Results: Similar alveolar development was observed between groups. No difference was seen between mean Lm values. Although the alveolar surface area was found to be higher in high-dose omega-3 group, the difference was not considered to be statistically significant. While the widest alveolar wall thickness was observed in the placebo group, alveolar wall thickness difference between high-dose omega-3 group and placebo group was found to be statistically significant (placebo Wt=17,8 ± 2.3 µm, low-dose omega −3 Wt=15,6 ± 2,5 µm, high-dose omega −3 Wt=14,2 ± 2 µm) (p < .05).Conclusions: Omega-3 fatty acids were observed to prevent alveolar wall thickness to some extent, though with no noticeable effect on hyperoxic lung injury.

Omega-3 fatty acid decreases oleic acid by decreasing SCD-1 expression in the liver and kidney of a cyclosporine-induced nephropathy rat model

Aim: Stearoyl-CoA desaturase (SCD)-1 and elongase-6 (Elovl-6) are associated with fatty acid (FA) synthesis. We evaluated the effect of omega-3 FA on erythrocyte membrane FA contents through SCD-1 and Elovl-6 expression in the liver and kidney of a cyclosporine (CsA)-induced rat model.Methods: Male Sprague Dawley rats were divided into control, CsA, and CsA treated with omega-3 FA groups. We measured SCD-1 and Elovl-6 expression levels via western blot and immunohistochemistry analysis.Results: Erythrocyte membrane oleic acid content was lower in the CsA with omega-3 FA group compared to the CsA group. Compared to the control group, CsA-induced rats showed elevated SCD-1 expression in the kidney and liver, which omega-3 FA treatment reversed. Elovl-6 expression was increased in the liver, but decreased in the kidney in CsA group compared to control, which omega-3 FA treatment also reversed.Conclusions: Omega-3 FA supplementation decreased erythrocyte membrane oleic acid content by modulating SCD-1 and Elovl-6 expression in the kidney and liver of CsA-induced rats.

Preventive effect of omega-3 fatty acids in a rat model of stress-induced liver injury.

Omega-3 fatty acids are gaining attention as a therapeutic agent of many diseases. Their protective effect in a variety of diseases has been demonstrated. To the best of our knowledge, this is the first study on omega-3 fatty acids related to acute cold-restraint stress (CRS) induced hepatic dysfunction in rats. Forty adult male Sprague-Dawley albino rats were used and classified into: control, omega-3 group, each rat was pretreated with omega-3 fatty acids; CRS group, rats were subjected to acute CRS for 6 hr; and CRS group pretreated with omega-3 fatty acids. Serum was obtained to determine corticosterone (CORT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and tumor necrosis factor-α (TNF-α) levels. Hepatic malondialdehyde (MDA) and total antioxidant capacity (TAC) levels were measured. Also, liver tissues were taken for histological examination and immunohistochemical assessment of the apoptotic marker, caspase-3. Results showed that pretreatment of stressed rats with omega-3 fatty acids led to significant decrease in hepatic MDA and increase in TAC levels. They reduced serum levels of CORT, ALT, AST, and TNF-α. Also, they improved liver damage and suppressed hepatic caspase-3 expression. In conclusion, pretreatment of stressed rats with omega-3 fatty acids has ameliorated stress-induced liver damage due to their antioxidant, anti-inflammatory, and antiapoptotic effects. So, they can be used to minimize stress complications on the liver.

Evaluation of the effect of systemic omega-3 polyunsaturated fatty acids on post-orthodontic relapse in a rabbit model

Introduction: Long term stability is the major goal of orthodontic treatment. Hence, a series of safe pharmacological agents have been investigated to increase osteoblastic activity around orthodontically moved teeth to help in retention and stability of their correction. Aim of the study: To evaluate the effect of systemic administration of Omega-3 fatty acids on post-orthodontic relapse, and to histologically assess bone changes concurrent with its administration in rabbits. Materials and Methods: Thirty two adult albino male rabbits were divided equally and randomly into two groups. Each group received NiTi coil springs installed on mandibular first molars and ligated to anterior incisors. Omega-3 or Saline were given from day one of orthodontic tooth movement (OTM) till end of relapse period by oral gavage. After 21 days of active OTM, appliances were removed from both groups to allow orthodontic relapse (OR); then amount and percentage of relapse were measuredon days 21, 28 and 42. Animals were sacrificed for histomorphometric analysis of alveolar bone remodeling. Results: A significant difference in relapse percentage was found on the third week of OR with means (66.04 ± 6.01 %) and (75.22 ± 13.61%) for experimental and control groups, respectively. Histomorphometric analysis showed a significant reduction in the area of active bone-resorptive lacunae and a significant increase in newly formed bone area related to omega-3 group. Conclusions: A strong evidence of the osteoblastic simulative effect of Omega-3 had been found with decreased percentage of OR after OTM.

The effect of Omega-3 fatty acid on Adiponectin and potential implication for obesity management

Objective: To evaluate the effect of 2 months use of omega-3 fatty acids on adiponectin and other parameters contribute to weight control in healthy obese volunteers like body mass index (BMI), waist and hip circumferences and to compare the concentrations of adiponectin between interventional groups and control groups. Design: Open–labeled randomized trial. Method: This study included seventy- eight volunteers, aged 20-55 years with different gender and BMI. The patients were divided into 2 groups, namely the omega-3 alone group which consisted of 25 obese subjects and the second one consisted of 26 obese subjects which represented the omega-3 and diet group. The subjects groups were followed for 2 months during which the above parameters were measured before starting therapy and at the end of the follow-up period using commercially available kits. The patient groups were compared with a control group consisted of 67 apparently healthy subjects. The determination of adiponectin concentration in human serum was done using ELISA technique Results: Significant differences were found regarding adiponecin (p=0.001) in the interventional groups in comparison with control group. The studied parameters were compared in the omega-3 groups and showed non-significant differences between the two studied groups concerning serum adiponectin (p=0.065). By comparing the studied parameters in the omega-3 alone group after 2 months of treatment, a significant differences were found in serum adiponectin (p=0.012). The use of omega-3 with diet for 2 months of treatment resulted in a significant increase in serum adiponectin (p=0.000). The percentage improvement in the studied parameters in the first group after 2 months of treatment showed highly significant increase in serum adiponectin (114.53%) with p-value (0.000). While in the second group, highly significant increase in serum adiponectin (214.10%) with p-value (0.000) were obtained. Conclusion: The level of Adiponectin was significantly increased in interventional groups compared to control. The level of Adiponectin was very significantly increased in omega-3 with diet group compared with omega-3 alone group which reflected on the improvement in anthropometric parameters such as weight and BMI. .

The Protective Effects of Omega3 on Ubiquitination and Protamination of Rat Sperm after Bleomycin, Etoposide, and Cisplatin Treatment

The purpose of this study is evaluation the protective effect of omega3 on rat sperm protamination and ubiquitination after treatment with Bleomycin, Etoposide and Cisplatin (BEP) drugs. In present study, 40 male rats were divided into four groups: Control, BEP, Omega3 and BEP + Omega3. Sperm protamination and ubiquitination were assessed using chromomycin A3 and immunofluorescence staining respectively. The mean percentage of ubiquitinated sperm in BEP group was significantly increased relative to control group (P < .001). But, the mean percentage of sperm protamination significantly decreased in BEP group relative to control group (P < .001). Rats in BEP + Omega3 group showed a significantly decreased in the mean percentage of sperm ubiquitination as compared to BEP group (P < .05) while, sperm protamination increased significantly relative to BEP group (P < .001). Administration of Omega3 after chemotherapy showed an improvement in sperm ubiquitination and protamination. Our data indicated that omega3 after chemotherapy may be beneficial for chromatin remodeling during spermatogenesis following BEP treatment.

Omega-3 polyunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: A double-blind randomized controlled trial

BackgroundThis study assessed whether a combined intervention of omega-3 polyunsaturated fatty acids (PUFAs) and psychoeducation better improved mild to moderate depression in workers compared to psychoeducation alone. MethodsThis study was a double-blinded, parallel group, randomized controlled trial that compared the intervention group, receiving omega-3 fatty acids, with a control group, receiving a placebo supplement. Participants receiving omega-3 fatty acids took 15 × 300 mg capsules per day for 12 weeks. The total daily dose of omega-3 PUFAs was 500 mg docosahexaenoic acid and 1000 mg eicosapentaenoic acid (EPA). The Beck Depression Inventory®-II (BDI-II) was used to assess the severity of depression after treatment. ResultsAfter 12 weeks of treatment, BDI-II scores were significantly lower in the placebo and omega-3 group, when compared to their respective baseline scores (Placebo: t = − 4.6, p < 0.01; Omega-3: t = − 7.3, p < 0.01). However, after 12 weeks of treatment, we found no significant difference between both groups with respect to changes in the BDI-II scores (0.7; 95% CI, − 0.7 to 2.1; p = 0.30). LimitationsThis study did not measure blood omega-3 fatty acid concentration and presented a high-dropout rate. Moreover, our results may not be generalizable to other regions. ConclusionsThe results show that a combination of omega-3 fatty acids and psychoeducation and psychoeducation alone can contribute to an improvement in symptoms in people with mild to moderate depression. However, there is no difference between the interventions in ameliorating symptoms of depression.

Effects of supplying omega-3 polyunsaturated fatty acids to gilts after weaning on metabolism and ovarian gene expression.

Omega-3 PUFA may benefit sow reproductive performance, but effects on weaned gilts are unknown. This study evaluated the effects of supplementing omega-3 PUFA to gilts after weaning on growth, metabolic markers, and gene expression of steroidogenic enzymes and hormone receptors. For 52 d, gilts in the control group were fed 100 g/d of regular diets, whereas gilts in the omega-3 group were fed 75 g/d of such diets plus 25 g/d of the microalgae Schizochytium sp. (3.5 g/d of omega-3 PUFA; n = 8 gilts/group). Blood samples were collected at day 0, day 21, and day 52. Total serum cholesterol levels were lower for the omega-3 group than for the control group (P < 0.05), but high-density lipoprotein-cholesterol levels were reduced at day 52 for both groups (P < 0.05). Gilts in the omega-3 group presented lower feed intake, better feed conversion, and less-intense immunolabeling for leptin and its receptor in the cytoplasm of oocytes included in primordial/primary follicles than gilts in the control group (P < 0.05). The expression of genes coding for cholesterol side-chain cleavage and aromatase enzymes and the LH receptor in follicular cells was lower for supplemented gilts (P < 0.05). Compared with controls, supplemented gilts presented decreased serum cholesterol levels and better feed conversion, but leptin presence and gene expression for steroidogenic enzymes and for the LH receptor were lower at ovarian level.

Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device.

Background Gastrointestinal bleeding (GIB) is a common complication seen in patients supported with left ventricular assist devices (LVADs) and is related to increased inflammation and angiogenesis. Omega-3 is an unsaturated fatty acid that possesses anti-inflammatory and antiangiogenic properties. This study aims to assess the prophylactic efficacy of treatment with omega-3 on the incidence of GIB in LVAD patients. Methods and Results Among consecutive 166 LVAD patients enrolled in this analysis, 30 patients (49 years old and 26 male) received 4 mg/d of omega-3 therapy for 310±87 days and 136 patients in the control group (58 years old and 98 male) were observed for 302±102 days. One-year GIB-free rate was significantly higher in the omega-3 group as compared with the control group (97% versus 73%; P=0.02). Omega-3 therapy was associated with the occurrence of GIB in both the univariate (hazard ratio, 0.12; 95% CI, 0.02-0.91; P=0.040) and multivariate Cox proportional hazard ratio analyses (hazard ratio, 0.13; 95% CI, 0.02-0.98; P=0.047). The frequency of GIB was significantly lower in the omega-3 group (0.08±0.42 versus 0.37±0.93 events/y; P=0.01), accompanied by significantly lower blood product transfusion and shorter days in the hospital. The frequency of GIB remained lower among the omega-3 group after matching for patient background characteristics (96% versus 73%, P=0.028). Conclusions LVAD patients treated with omega-3 had a significant increase in freedom from GIB. A randomized controlled study is warranted to evaluate the use of omega-3 in LVAD patients.

Omega-3 Supplementation Improves Pruritus in Continuous Ambulatory Peritoneal Dialysis Patients: A Crossover Randomized Pilot Clinical Trial.

Objective:Pruritus is a prevalent skin condition in end-stage renal disease patients. Omega-3 fatty acids have been shown to reduce pruritus in hemodialysis patients. Our objective was to assess the effect of 3 g/day omega-3 supplementation on pruritus among continuous ambulatory peritoneal dialysis (CAPD) patients.Methods:In this two-period, two-sequence crossover randomized clinical trial, 40 eligible subjects (CAPD patients who complained of pruritus for more than 8 weeks) were randomized to 3 g of omega-3 (n = 20) or identical placebo capsules (n = 20) for 4 weeks. After a wash-out period of 6 weeks, patients were crossed over to the alternate treatment option. Pruritus intensity was assessed using the visual analog scale (VAS) at baseline, 2-and 4-weeks post-intervention in each study period. Both patients and investigators were blinded to the study protocol.Findings:No significant carry-over effect was detected. The mean pruritus score (VAS) in the omega-3 group compared with placebo group after the first (−3.02 vs. −0.48, P < 0.001) and second (−4.09 vs. −0.43, P < 0.001) intervention periods showed higher significant decrease.Conclusion:In summary, omega-3 supplementation is an effective treatment for pruritus alleviation in CAPD patients. Further studies are needed to determine the mechanisms underlying antipruritic effects of omega-3.

Effect of Botanical Extracts on Amino Acid and Fatty Acid Profile of Broiler Meat

ABSTRACT The objectives of current study were to evaluate the effect of botanical extracts as antioxidants on amino - and fatty acids profile of broiler meat. In total, 200 one-day-old broiler chicks were divided according to a completely randomized design into eight dietary treatments with five replicates of five chicks each. Dietary treatments were: A - positive control (PC) with antibiotics and synthetic antioxidants, B - negative control (NC), C - NC+Trigonellafoenum-graecum, D -NC+Nigella sativa seed, E -NC+Violaodorata, F -NC+Trachyspermumammi, G -PC+Trachyspermumammi+Trigonellafoenum-graecum+Violaodorata, and H -NC+ Trachyspermumammi, Trigonellafoenum-graecum and Viola odorata. Meat amino - and fatty acid contents were analyzed after slaughter at 35 days of age. Data were submitted to one-way analysis of variance and means were compared by Duncan’s Multiple Range test. The levels of histidine, isoleucine, leucine, lysine and threonine were significantly higher (p≤0.05) in the H, F, E, H and F groups respectively. Arginine, tryptophan, valine, methionine, and phenylalanine were significantly higher (p≤0.05) in the C, F, E, G and H groups. Total essential amino acid levels were highest (40.36%) in C group (p≤0.05). The meat of H broilers presented significantly higher (p≤0.05) unsaturated fatty acids (54.8%) and omega-3 contents (2.77%) and the lowest saturated fatty acid content (44.8%). Group F present the highest linoleic acid and omega-6 levels and group H the highest (p≤0.05) arachidonic and eicosapentaenoic acid (EPA) contents. It was concluded that botanical extracts aid health-beneficial meat production and the simultaneous inclusion of Trachyspermumammi, Trigonellafoenum-graecum, and Viola odorata in broiler diets is a more suitable option than the other dietary regimes.

Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial.

Smoking-induced oxidative stress is thought to contribute to lower levels of omega-3 fatty acids in plasma and brain tissue. This lower level leads to impaired function in a dopaminergic system related to dependence and craving. The aim of this study was to evaluate the effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males. In this double-blind, randomized clinical trial, 54 heavy-smoker males (smoke ⩾20 cigarettes per day) were randomly selected to receive either five capsules of fish-oil-derived omega-3 fatty acid supplements ( n = 27, each 1 g capsule containing 180 mg of eicosapentaenoic acid and 120 mg of docosahexanoic acid) or a placebo ( n = 27) for 3 months. The psychometric evaluations (nicotine dependence and cigarette craving), biochemical markers (urinary cotinine, serum total antioxidant capacity and total oxidant status) and self-reported smoking status were used to assess the cigarette craving and oxidative stress index (oxidative stress index = total oxidant status/total antioxidant capacity). There was a greater reduction in levels of nicotine dependence, cigarette craving and cigarettes smoked per day in the omega-3 fatty acid group compared to the placebo group, and the difference between the two groups increased from baseline to 3-month follow up. The model estimated that these differences were statistically significant ( p < 0.001, p < 0.001 and p < 0.001, respectively). Also, a significant decrease was observed in levels of total oxidant status ( p = 0.008) and oxidative stress index ( p = 0.011) in the omega-3 fatty acid group after intervention. This study showed that high-dose omega-3 fatty acid supplementation appears to be useful in reducing cigarette craving and oxidative stress index in heavy-smoker males.

Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial

ObjectivesThe goal of this study was to test the effects of long-chain omega-3 fatty acid supplementation on omega-3 levels, depressive symptoms, and other psychosocial factors, as well as other chronic heart failure (CHF)-related functional measures. BackgroundPatients with CHF and depression had low blood omega-3 concentrations that were associated with an elevated risk of mortality. MethodsThis study was a randomized, double-blind, placebo-controlled pilot clinical trial using a 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g and an almost pure EPA at 2 g, compared with a matched placebo, daily for 12 weeks for patients with CHF and major depressive disorder. Statistical analyses included the intention-to-treat population and “completers” (defined as participants consuming ≥70% of the capsules and completing the final endpoint evaluation between 10 and 14 weeks). ResultsA total of 108 patients with CHF and major depressive disorder and a score ≥18 on the Hamilton Depression Scale who were randomized at 1:1:1 to the 3 interventions at 3 enrolling centers from June 12, 2014, to May 19, 2016; 80 (74.1%) qualified as completers. Intention-to-treat analyses revealed that the levels of all omega-3 variables were significantly elevated in the omega-3 groups, whereas the placebo group showed little change; there were no between-group differences with overall depression measurements. Per-protocol exploratory analyses showed that scores on the social functioning measurement of the 36-item Short Form Health Survey improved notably in the 400/200 EPA/DHA (p = 0.040) and EPA (p = 0.10) groups compared with the placebo group. Spearman correlation analysis indicated that increased omega-3 indices were associated with improved cognitive depressive symptoms. ConclusionsOmega-3 supplementation resulted in significant increases in omega-3 levels in red blood cell counts, corresponding to a particular compound of omega-3. Changes in cognitive depressive symptoms and social function were in favor of the omega-3 supplementation. Further studies with larger sample sizes are necessary to confirm the benefits of omega-3 supplementation on modifying psychosocial factors for patients with CHF. (Omega-3 Supplementation for Co-Morbid Depression and Heart Failure Treatment [OCEAN]; NCT02057406)

Impact of Omega-3 Supplementation on High Sensitive C-Reactive Protein Level and 30-Day Major Adverse Cardiac Events After the Implementation of Coronary Stent in Patients with Chronic Kidney Disease: A Randomized Clinical Study.

Purpose: Studies have revealed that patients with chronic kidney disease (CKD) are more susceptible to adverse effects of percutaneous coronary intervention (PCI). In addition, the role of elevated high sensitive C-reactive protein (hs-CRP) in the prediction of adverse cardiac outcomes after coronary stent implantation has already been shown. Therefore, in this study, we aimed to evaluate the effect of omega-3 supplementation on hs-CRP and 30-day major adverse cardiac events (MACE) in patients with CKD undergoing elective PCI.Methods: In this randomized trial, 80 CKD patients who were candidates for elective PCI, were randomly assigned to two groups; the first group received a single dose of omega-3 (2500 mg, 12 h before PCI) as well as the standard drug regimen of PCI and the second group received placebo plus the standard therapy (325 mg loading dose of aspirin, 600 mg loading dose of clopidogrel, and weight-adjusted intravenous heparin). Hs-CRP levels were measured at baseline and 24 h after the intervention as a primary endpoint. The secondary endpoint was the incidence of MACE over a 30-day period after PCI.Results: Omega-3 did not significantly decrease post-PCI serum level of hs-CRP; however, the overall 30-day MACE was significantly lower in the omega-3 group compared to the control group (p=0.05).Conclusion: Our results revealed the positive effect of the omega-3 supplement on decreasing 30-day MACE; hence, omega-3 may be considered as an effective adjunctive therapy to the standard drug regimen used before PCI. The evaluation of the effect of omega-3 on long-term MACE is recommended for future studies.